who reports todayUS earnings, drawn as flowsMy portfolio

← Who reports today · Health Care

Merck (MRK) earnings date & Q3 2026 results

US GAAP · quarter ended 09/30/2026 · released Oct 29

Net Income Attributable to Merck & Co., Inc.

$5,065M

down 12.4% y/y

Sales

$18,085M

up 4.7% y/y

Next report

~ Feb 2

not announced yet

The quarter in brief

Merck's Q3 2026 sales rose 5% to $18,085 million, but GAAP net income fell 12% to $5,065 million and diluted EPS dropped to $2.04 from $2.32. Higher costs, a $400 million license charge and a swing in other expense outweighed sales growth.

Key growth driver: KEYTRUDA/KEYTRUDA QLEX sales grew 6% to $8.6 billion, WINREVAIR rose 93% to $694 million and GARDASIL/GARDASIL 9 rose 14% to $1,995 million. · by the Q3 2026 report

All figures in $M.

Sankey diagram of MRK (Merck) earnings report for Q3 2026: revenue, costs and profitSales$18,085 · +4.7%Cost of sales$4,892 · +26.9%Selling, generalandadministrative$2,886 · +9.6%Research anddevelopment$4,537 · +7.2%Restructuringcosts$184 · +291%Other (income)expense, net$27 · vs −$238Income BeforeTaxes$5,559 · −17.6%30.7% marginIncome Tax Provision$492 · −48.6%8.9% effective rateNet Income Attributable toNoncontrolling Interests$2 · +0.0%Net Income Attributable toMerck & Co., Inc.$5,065 · −12.4%$2.04/sh · 28.0% margin
Sankey diagram of MRK (Merck) earnings report for Q3 2026: revenue, costs and profit
Line itemAmount and change
Sales$18,085 · +4.7%
Cost of sales$4,892 · +26.9%
Selling, general and administrative$2,886 · +9.6%
Research and development$4,537 · +7.2%
Restructuring costs$184 · +291%
Other (income) expense, net$27 · vs −$238
Income Before Taxes$5,559 · −17.6% · 30.7% margin
Income Tax Provision$492 · −48.6% · 8.9% effective rate
Net Income Attributable to Noncontrolling Interests$2 · +0.0%
Net Income Attributable to Merck & Co., Inc.$5,065 · −12.4% · $2.04/sh · 28.0% margin

Verdict: Merck's Q3 2026 sales rose 5% to $18,085 million, but GAAP net income fell 12% to $5,065 million and diluted EPS dropped to $2.04 from $2.32. Higher costs, a $400 million license charge and a swing in other expense outweighed sales growth.

Merck narrowed its full-year 2026 sales outlook to $66.8–67.3 billion from $66.3–67.3 billion. Non-GAAP EPS guidance was raised to $2.77–2.82 from $2.66–2.76, including one-time charges of $3.62 (Cidara), $2.31 (Terns) and $0.12 (SciBrunch) per share. The full-year non-GAAP tax rate outlook is now 32.0%–33.0% versus 35.0%–36.0% before.

Source and notation

Source: Merck & Co. earnings release, 8-K EX-99 of 10/29/2026 (SEC EDGAR).

Open as an image: Merck (MRK), Q3 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0

Cite / embed this chart

Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).

Credit line
Chart: “Merck (MRK) Q3 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/mrk. Licensed under CC BY 4.0.
HTML: image with link and credit
<figure>
  <a href="https://whoreportstoday.com/t/mrk"><img src="https://whoreportstoday.com/t/mrk/img/merck-and-co-mrk-earnings-sankey.png" alt="Merck (MRK) Q3 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a>
  <figcaption>Source: <a href="https://whoreportstoday.com/t/mrk">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption>
</figure>
Direct link to the image (PNG)
https://whoreportstoday.com/t/mrk/img/merck-and-co-mrk-earnings-sankey.png
Link for your article text
<a href="https://whoreportstoday.com/t/mrk">Merck (MRK) Q3 2026 earnings chart (Who Reports Today)</a>

The image link always shows the latest report’s chart and will update with the next quarter. To keep this exact chart in your article, save the PNG and upload it yourself — the license allows that. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.

Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. · Text: Wikipedia, CC BY-SA 4.0, abridged

The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fifth on the list of largest biomedical companies by revenue. Market share (US pharma & biotech): ≈9% by TTM revenue.

Heads-up

Company reports

Q3 2026latest breakdownMerck's Q3 2026 sales rose 5% to $18,085 million, but GAAP net income fell 12% to $5,065 million and diluted EPS dropped…
Q2 2026A GAAP loss quarter manufactured almost entirely by one deal — the $5.7B Terns acquisition charge sits in R&D with no…

Company guidance

PeriodCompany guidanceA year agoImplied growth
FY2026revenue $66.8–67.3BEPS (non-GAAP) $2.77–2.82revenue $65BEPS (GAAP) $7.28revenue +3…4%

Same quarter a year ago (ended December 31, 2025): revenue $16.4B, EPS (GAAP) $1.19

How we calculate

Implied growth compares the low and high ends of the company's range with the same period a year ago (midpoint: +3%).

EPS growth is not calculated: the guidance is non-GAAP (adjusted), while the year-ago EPS is GAAP, so the two are not comparable.

Year-ago figures are GAAP, from the company's SEC filings (XBRL); EPS is diluted.

Guidance comes from the company's earnings release (Form 8-K filed Oct 29, 2026); every figure is checked against the release text.

The company's release on SEC EDGAR (8-K exhibit) ↗

MRK earnings history: past report dates

Oct 29, 2026 Thu6:43 ambefore market openSep 30, 2026$18.1B+5% y/y$2.04−12% y/y
Aug 4, 2026 Tue6:47 ambefore market openJun 30, 2026$16.6B+5% y/y−$0.54
Apr 30, 2026 Thu6:53 ambefore market openMar 31, 2026$16.3B+5% y/y−$1.72
Feb 3, 2026 Tue6:38 ambefore market openDec 31, 2025≈$16.4B+5% y/y≈$1.19−20% y/y
Oct 30, 2025 Thu6:40 ambefore market openSep 30, 2025$17.3B+4% y/y$2.32+87% y/y
Jul 29, 2025 Tue6:42 ambefore market openJun 30, 2025$15.8B−2% y/y$1.76−18% y/y
Apr 24, 2025 Thu6:45 ambefore market openMar 31, 2025$15.5B−2% y/y$2.01+7% y/y
Feb 4, 2025 Tue6:45 ambefore market openDec 31, 2024≈$15.6B+7% y/y≈$1.49
Oct 31, 2024 Thu6:44 ambefore market openSep 30, 2024$16.7B+4% y/y$1.24−33% y/y
Jul 30, 2024 Tue6:41 ambefore market openJun 30, 2024$16.1B+7% y/y$2.14
Apr 25, 2024 Thu6:41 ambefore market openMar 31, 2024$15.8B+9% y/y$1.87+68% y/y
Feb 1, 2024 Thu6:39 ambefore market openDec 31, 2023≈$14.6B+6% y/y≈−$0.48
Oct 26, 2023 Thu6:38 ambefore market openSep 30, 2023$16.0B+7% y/y$1.86+45% y/y
Aug 1, 2023 Tue6:46 ambefore market openJun 30, 2023$15.0B+3% y/y−$2.35
Apr 27, 2023 Thu6:43 ambefore market openMar 31, 2023$14.5B−9% y/y$1.11−35% y/y
Feb 2, 2023 Thu6:42 ambefore market openDec 31, 2022≈$13.8B+2% y/y≈$1.18−20% y/y
Show all 16 reports since 2023Show fewer
How we count

Report date and time — when the company filed its results press release with the SEC (Form 8-K, Item 2.02); the regular session runs 9:30 am – 4:00 pm ET. Companies that file the 8-K late in the evening publish the release the next morning: the date is that morning, before market open, and the evening filing time is not shown. Revenue and diluted EPS — the company’s XBRL filings, EPS adjusted for stock splits; ≈ — fourth quarter derived as full year minus three quarters. Source: SEC EDGAR.

Merck: 15-year financials

202565,01118,25412,3608,176
202464,16817,11718,0967,840
202360,1153659,1437,445
202259,28314,51914,7077,012
202148,70413,0498,6746,610
2020—*7,0675,8246,215
201939,1219,84310,0715,695
201842,2946,2208,3075,172
201740,1222,3944,5635,167
201639,8073,9208,7625,124
201539,4984,44211,2555,117
201442,23711,9206,6725,170
201344,0334,40410,1065,157
201247,2676,1688,0685,116
201148,0476,27210,6604,691

$ millions, annual 10-K reports on SEC EDGAR (US GAAP)*.

* Sources
How we calculate

Figures are annual report lines; if a year was later restated (discontinued operations, mergers), we use the latest filing that shows it. Free cash flow is operating cash flow minus capital expenditures; dividends are cash paid to common shareholders during the year. “—” means the line isn’t in the filing. “—*” in revenue: we don’t show that year’s revenue — the annual figure is more than 2% off the sum of the quarters, or the filing tags several revenue lines and the total can’t be pinned down. The table starts in 2011; where the listed issuer changed (holding reorganization, redomicile), earlier years come from the predecessor’s filings.

Merck: 15-year balance sheet

YearAssetsEquityDebtCashCurrent assetsCurrent liabilities
2025136,86652,60649,30014,56543,51628,327
2024117,10646,31337,10013,24238,78228,420
2023106,67537,58135,1006,84132,16825,694
2022109,16045,99130,70012,69435,72224,239
2021105,69438,18433,1008,09630,26623,872
202091,58825,31731,8008,05027,76427,327
201984,39725,90726,3009,67627,48322,220
201882,63726,70125,1007,96525,87522,206
201787,87234,33624,3536,09224,76618,614
201695,37740,08824,5746,51530,61417,204
2015101,67744,67626,1298,52429,75119,201
201498,16748,64719,6997,44132,60518,397
2013105,64549,76522,63915,62135,68517,868
2012106,13253,02018,05413,45134,85718,348
2011105,12854,51717,51513,53133,18116,245

$ millions, at fiscal year-end*.

* Sources
How we calculate

Annual balance sheet figures. “—” means no data; zero appears only when a numeric zero is present. Metrics with fewer than two values are omitted. Annual amounts use the financial screener data, in the reporting currency. Equity is attributable to shareholders where available, otherwise total equity including noncontrolling interests. Debt and cash follow the stored figures: they may include leases and restricted cash. Snapshot updated: .

Cash flow

9 months ended 2026-09-30 · $M

LineThis periodYear agoΔ
Operating cash flowcash the business generated15,84613,615+2,231
· incl. D&A (non-cash add-back)depreciation & amortization1,9061,552
· incl. stock-based comp (non-cash)share-based compensation852615
Capexpurchases of property & equipment−2,924−3,079+155
Free cash flow ≈operating cash flow − capex12,92210,536+2,386
Investing activities, netcapex, acquisitions, securities−17,131−2,540−14,591
· incl. acquisitionsbusinesses net of cash acquired−8,7790−8,779
Financing activities, netdebt, buybacks, dividends−3,651−6,673+3,022
· incl. buybacksrepurchases of common stock−2,284−3,832+1,548
· incl. dividends paid−6,348−6,158−190
FX effect on cash−102540−642
Net change in cash−5,0384,942−9,980
How to read the table

Cash flow is cumulative from the start of the fiscal year, rather than a single quarter. Lines marked ≈ are derived. Green Δ means more cash in (or less out) than a year ago. ≈ in Δ means a difference that rounds to zero at the displayed precision.

Shareholders’ equity at Sep 30, 2026: $44.9B (34% of total assets). Compare with other S&P 500 companies →

Corporate governance

1.5/2mostly good

  • Jan 2016Merck agreed to settle the Vioxx shareholder class action for $830M plus attorneys' fees (insurance covered about $380M). sec.gov ↗
  • Feb 2013Merck will pay $215M and $473M (for Schering-Plough) to settle shareholder suits over the ENHANCE trial (Vytorin/Zetia). sec.gov ↗
2 more facts and scoring

How the company treats minority shareholders: 2 — well, 0 — systematically poorly.

  • Feb 20262025 10-K: a single class of common stock; a new shareholder class action and derivative suits filed in 2025 are disclosed — not settled. sec.gov ↗
  • Dec 2025Dividend per share rose from $2.48 (2020) to $3.28 (2025); share count −1.3% over 5 years. data.sec.gov ↗

Scoring: 2.0 −0.25 (criterion 9: Vioxx shareholder suit settled for $830M + attorneys' fees, January 2016, more than 10 years ago — half of 0.5) −0.25 (criterion 9: shareholder suit over the ENHANCE trial (Vytorin/Zetia) settled for $688M together with Schering-Plough, 2013, more than 10 years ago — half of 0.5) = 1.5

Share classes
Single class — MRK common stock on the NYSE (cover of 2025 10-K).
Dilution
Diluted share count 2020→2025 −1.3% (XBRL); SBC 1.3% of revenue.
Disclosure
Full 10-K/10-Q reporting.
Dividends
Dividend per share raised every year: $2.48 (2020) → $3.28 (2025); the Organon spin-off (2021) came without a dividend cut.
Lawsuits & regulators
Shareholder suits over Vioxx ($830M, 2016) and ENHANCE ($688M, 2013) were settled — both more than 10 years ago; the new 2025 class action and derivative suits are not settled — no deduction; no SEC disclosure cases.
Related parties
2026 proxy: a related-party transaction policy is in place, no material transactions disclosed; no controlling shareholder.

How the score works · checked as of Oct 2026

Included in screener lists: S&P 500 companies that paid dividends 10 years without a gap

Merck (MRK) earnings: FAQ

When is MRK's next earnings date?

We have not yet seen an announcement of the date from Merck (MRK). Based on last year's report on Feb 3, 2026, the next report is expected around Feb 2, 2027.

What time does MRK report earnings?

Merck usually reports before market open: its latest results release was filed with the SEC at 6:43 am ET on Oct 29, 2026.

When did MRK last report earnings?

Merck reported Q3 2026 results on Oct 29, 2026.

What has Merck guided for FY2026?

Company guidance for FY2026: revenue $66.8–67.3B; EPS (non-GAAP) $2.77–2.82. A year ago (FY2025): revenue $65B, EPS (GAAP) $7.28. Implied growth: revenue +3…4%. Source: the company's earnings release (Form 8-K filed Oct 29, 2026).

Where can I find Merck's financial statements?

On SEC EDGAR: quarterly reports (10-Q), the annual report (10-K) and earnings releases (8-K). The “Verified” badge next to the chart links to MRK's filings; this page breaks the latest report down in a Sankey chart.

What was MRK's net income in Q3 2026?

Merck reported net income of $5,065M for Q3 2026 (−12.4% year over year), under US GAAP.

Does Merck pay dividends?

Yes. In 2025, Merck paid $8,176M in dividends on its common stock, per its 10-K. Earlier years are in the 15-year table above.

How has Merck's revenue changed since 2011?

Per its 10-K filings, revenue grew 1.4x: $48,047M in 2011 and $65,011M in 2025. The latest year is the highest in the table. Year-by-year figures are in the table above.

New to earnings reports? Start with how to read an earnings report.

Get it every Monday: who reports this week

Once a week: companies that announced report dates for the week ahead (US and Canada), fresh report breakdowns with charts. Free, no account needed.

Only dates announced by companies. No stock prices. Not investment advice.

More reports: MRNA · Q2 2026 · MTD · Q3 2026 · PFE · Q3 2026 · PODD · Q3 2026 · REGN · Q3 2026 · RMD · Q1 FY2027 · RVTY · Q3 2026 · SOLV · Q2 2026 · STE · Q2 FY2027 · SYK · Q3 2026 · all reports

Cookies the site needs and, with your consent, Google Analytics — privacy policy